{"transactions":[{"id":881343,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-25T19:57:25.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":2579,"price":41.9839,"value":108276.4781,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":45727,"source":{"system":"sec-edgar","filing":"0001733883-26-000006","document":"form4-02262026_120221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733883/000173388326000006/form4-02262026_120221.xml","form_type":"4"}},{"id":890212,"issuer":{"id":6445,"kind":"organization","name":"Caribou Biosciences, Inc."},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2026-02-20T22:27:42.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":1.8,"expiration_date":"2036-02-19","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001733883-26-000004","document":"wk-form4_1771626459.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619856/000173388326000004/wk-form4_1771626459.xml","form_type":"4"}},{"id":915680,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-06T20:00:07.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":42.74,"expiration_date":"2036-02-03","underlying":"Class A Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001733883-26-000002","document":"form4-02062026_080203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733883/000173388326000002/form4-02062026_080203.xml","form_type":"4"}},{"id":915679,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-06T20:00:07.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Class A Common Stock underlying the restricted stock units (\"RSUs\") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 643 shares of Class A Common Stock acquired on March 13, 2025 and 763 shares of Class A Common Stock acquired on September 12, 2025 under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":48306,"source":{"system":"sec-edgar","filing":"0001733883-26-000002","document":"form4-02062026_080203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733883/000173388326000002/form4-02062026_080203.xml","form_type":"4"}},{"id":1252241,"issuer":{"id":6445,"kind":"organization","name":"Caribou Biosciences, Inc."},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2025-02-22T01:14:38.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":40500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2026, subject to the reporting person continuing to provide service to the Issuer\nthrough each such vesting date."}],"balance_after":40500,"derivative":{"exercise_price":1.41,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":40500},"source":{"system":"sec-edgar","filing":"0001733883-25-000003","document":"wk-form4_1740186872.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619856/000173388325000003/wk-form4_1740186872.xml","form_type":"4"}},{"id":1254840,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-20T16:05:47.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":53800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48 of the shares subject to the stock option will vest and become exercisable on March 18, 2025, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":53800,"derivative":{"exercise_price":29.18,"expiration_date":"2035-02-17","underlying":"Class A Common Stock","underlying_shares":53800},"source":{"system":"sec-edgar","filing":"0001415889-25-004844","document":"form4-02202025_090230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733883/000141588925004844/form4-02202025_090230.xml","form_type":"4"}},{"id":1254839,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Class A Common Stock","published_at":"2025-02-20T16:05:47.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":26900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Class A Common Stock underlying the restricted stock units (\"RSUs\") under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":26900,"source":{"system":"sec-edgar","filing":"0001415889-25-004844","document":"form4-02202025_090230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733883/000141588925004844/form4-02202025_090230.xml","form_type":"4"}},{"id":1459194,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-07-03T16:05:19.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4 of the shares subject to the option vest on July 1, 2025, and 1/48 of the shares vest monthly thereafter, subject to continuous service of the Reporting Person through each vesting date."}],"balance_after":160000,"derivative":{"exercise_price":36.29,"expiration_date":"2034-06-30","underlying":"Class A Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001415889-24-019162","document":"form4-07032024_080715.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733883/000141588924019162/form4-07032024_080715.xml","form_type":"4"}},{"id":1624584,"issuer":{"id":6445,"kind":"organization","name":"Caribou Biosciences, Inc."},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2024-02-22T22:01:35.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":39500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2025, subject to the reporting person continuing to provide service to the Issuer through each such vesting date."}],"balance_after":39500,"derivative":{"exercise_price":6.81,"expiration_date":"2034-02-19","underlying":"Common Stock","underlying_shares":39500},"source":{"system":"sec-edgar","filing":"0001628280-24-006407","document":"wk-form4_1708639272.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619856/000162828024006407/wk-form4_1708639272.xml","form_type":"4"}},{"id":1995272,"issuer":{"id":6445,"kind":"organization","name":"Caribou Biosciences, Inc."},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2023-02-23T21:46:57.000Z","date":"2023-02-21","kind":"grant","acquired":true,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 21, 2024,  subject to the reporting person continuing to provide service to the Issuer through each such vesting date."}],"balance_after":21500,"derivative":{"exercise_price":6.12,"expiration_date":"2033-02-20","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0001619856-23-000016","document":"wf-form4_167718878109697.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000016/wf-form4_167718878109697.xml","form_type":"4"}},{"id":2141033,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:15:43.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":28628,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":29.87,"underlying":"Common Stock","underlying_shares":28628},"source":{"system":"sec-edgar","filing":"0000899243-22-033150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033150/doc4.xml","form_type":"4"}},{"id":2141032,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:15:43.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":38739,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":44.48,"underlying":"Common Stock","underlying_shares":38739},"source":{"system":"sec-edgar","filing":"0000899243-22-033150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033150/doc4.xml","form_type":"4"}},{"id":2141031,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:15:43.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":38500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":65.82,"underlying":"Common Stock","underlying_shares":38500},"source":{"system":"sec-edgar","filing":"0000899243-22-033150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033150/doc4.xml","form_type":"4"}},{"id":2141030,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:15:43.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":48.44,"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-22-033150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033150/doc4.xml","form_type":"4"}},{"id":2141029,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:15:43.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":55000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":54.05,"underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000899243-22-033150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033150/doc4.xml","form_type":"4"}},{"id":2141028,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T16:15:43.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":42400,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":42400},"source":{"system":"sec-edgar","filing":"0000899243-22-033150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033150/doc4.xml","form_type":"4"}},{"id":2141027,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T16:15:43.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":26454,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":26454},"source":{"system":"sec-edgar","filing":"0000899243-22-033150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033150/doc4.xml","form_type":"4"}},{"id":2141026,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T16:15:43.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":15460,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15460},"source":{"system":"sec-edgar","filing":"0000899243-22-033150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033150/doc4.xml","form_type":"4"}},{"id":2141025,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T16:15:43.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":13814,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13814},"source":{"system":"sec-edgar","filing":"0000899243-22-033150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033150/doc4.xml","form_type":"4"}},{"id":2141024,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T16:15:43.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":10935,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10935},"source":{"system":"sec-edgar","filing":"0000899243-22-033150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033150/doc4.xml","form_type":"4"}},{"id":2141023,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T16:15:43.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":3125,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0000899243-22-033150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033150/doc4.xml","form_type":"4"}},{"id":2141022,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-10-06T16:15:43.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":34384,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation (\"Parent\"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of the effective time of the Merger (the \"Effective Time\") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the \"Merger Consideration\"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-033150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033150/doc4.xml","form_type":"4"}},{"id":2141021,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-10-06T16:15:43.000Z","date":"2022-09-28","kind":"gift","acquired":false,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":34384,"source":{"system":"sec-edgar","filing":"0000899243-22-033150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033150/doc4.xml","form_type":"4"}},{"id":2165017,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-09-06T19:00:38.000Z","date":"2022-09-01","kind":"exercise","acquired":false,"shares":2208,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":15460,"derivative":{"underlying":"Common Stock","underlying_shares":2208},"source":{"system":"sec-edgar","filing":"0000899243-22-030479","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322030479/doc4.xml","form_type":"4"}},{"id":2165016,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-09-06T19:00:38.000Z","date":"2022-09-01","kind":"exercise","acquired":false,"shares":2763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":13814,"derivative":{"underlying":"Common Stock","underlying_shares":2763},"source":{"system":"sec-edgar","filing":"0000899243-22-030479","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322030479/doc4.xml","form_type":"4"}},{"id":2165015,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-09-06T19:00:38.000Z","date":"2022-09-01","kind":"tax_withholding","acquired":false,"shares":2103,"price":68.15,"value":143319.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,971 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":56384,"source":{"system":"sec-edgar","filing":"0000899243-22-030479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322030479/doc4.xml","form_type":"4"}},{"id":2165014,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-09-06T19:00:38.000Z","date":"2022-09-01","kind":"exercise","acquired":true,"shares":2208,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":58487,"source":{"system":"sec-edgar","filing":"0000899243-22-030479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322030479/doc4.xml","form_type":"4"}},{"id":2165013,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-09-06T19:00:38.000Z","date":"2022-09-01","kind":"exercise","acquired":true,"shares":2763,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":56279,"source":{"system":"sec-edgar","filing":"0000899243-22-030479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322030479/doc4.xml","form_type":"4"}},{"id":2165012,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-09-06T19:00:38.000Z","date":"2022-08-31","kind":"grant","acquired":true,"shares":365,"price":25.37,"value":9260.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":53516,"source":{"system":"sec-edgar","filing":"0000899243-22-030479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322030479/doc4.xml","form_type":"4"}},{"id":2195191,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-08-03T18:01:04.000Z","date":"2022-08-01","kind":"exercise","acquired":false,"shares":3645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":10935,"derivative":{"underlying":"Common Stock","underlying_shares":3645},"source":{"system":"sec-edgar","filing":"0000899243-22-027635","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322027635/doc4.xml","form_type":"4"}},{"id":2195190,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-08-03T18:01:04.000Z","date":"2022-08-01","kind":"exercise","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":3125,"derivative":{"underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0000899243-22-027635","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322027635/doc4.xml","form_type":"4"}},{"id":2195189,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-08-03T18:01:04.000Z","date":"2022-08-01","kind":"tax_withholding","acquired":false,"shares":2342,"price":32.4,"value":75880.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,770 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":53151,"source":{"system":"sec-edgar","filing":"0000899243-22-027635","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322027635/doc4.xml","form_type":"4"}},{"id":2195188,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-08-03T18:01:04.000Z","date":"2022-08-01","kind":"exercise","acquired":true,"shares":6770,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 299 shares of Common Stock acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":55493,"source":{"system":"sec-edgar","filing":"0000899243-22-027635","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322027635/doc4.xml","form_type":"4"}},{"id":2265153,"issuer":{"id":6445,"kind":"organization","name":"Caribou Biosciences, Inc."},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Common Stock","published_at":"2022-05-19T00:38:27.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable in three equal annual installments beginning May 18, 2023."}],"balance_after":44000,"derivative":{"exercise_price":9.12,"expiration_date":"2032-05-17","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001209191-22-030288","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619856/000120919122030288/doc4.xml","form_type":"4"}},{"id":2303444,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-04-05T19:00:13.000Z","date":"2022-04-01","kind":"exercise","acquired":false,"shares":4375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019, and with respect to 1/6th of the remaining underlying shares on a semi-annual basis thereafter through April 1, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019, and with respect to 1/6th of the remaining underlying shares on a semi-annual basis thereafter through April 1, 2022."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4375},"source":{"system":"sec-edgar","filing":"0000899243-22-013880","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322013880/doc4.xml","form_type":"4"}},{"id":2303443,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-04-05T19:00:13.000Z","date":"2022-04-01","kind":"tax_withholding","acquired":false,"shares":1513,"price":35.91,"value":54331.83,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,375 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":48424,"source":{"system":"sec-edgar","filing":"0000899243-22-013880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322013880/doc4.xml","form_type":"4"}},{"id":2303442,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-04-05T19:00:13.000Z","date":"2022-04-01","kind":"exercise","acquired":true,"shares":4375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":49937,"source":{"system":"sec-edgar","filing":"0000899243-22-013880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322013880/doc4.xml","form_type":"4"}},{"id":2352628,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2022-03-03T21:12:16.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":28628,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares of Common Stock underlying the stock option vest in 16 equal quarterly installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":28628,"derivative":{"exercise_price":29.87,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":28628},"source":{"system":"sec-edgar","filing":"0000899243-22-009262","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322009262/doc4.xml","form_type":"4"}},{"id":2352627,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-03T21:12:16.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":17668,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of Common Stock underlying the RSUs vest in two installments, if at all, based on (i) the Issuer's total shareholder return percentile ranking relative to the companies in the NASDAQ Biotechnology Index for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date, and (ii) the percentage of patient share relative to a comparator group for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of Common Stock underlying the RSUs vest in two installments, if at all, based on (i) the Issuer's total shareholder return percentile ranking relative to the companies in the NASDAQ Biotechnology Index for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date, and (ii) the percentage of patient share relative to a comparator group for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":17668,"derivative":{"underlying":"Common Stock","underlying_shares":17668},"source":{"system":"sec-edgar","filing":"0000899243-22-009262","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322009262/doc4.xml","form_type":"4"}},{"id":2352626,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-03T21:12:16.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":17668,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":17668,"derivative":{"underlying":"Common Stock","underlying_shares":17668},"source":{"system":"sec-edgar","filing":"0000899243-22-009262","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322009262/doc4.xml","form_type":"4"}},{"id":2352625,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-03T21:12:16.000Z","date":"2022-03-01","kind":"exercise","acquired":false,"shares":2763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":16577,"derivative":{"underlying":"Common Stock","underlying_shares":2763},"source":{"system":"sec-edgar","filing":"0000899243-22-009262","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322009262/doc4.xml","form_type":"4"}},{"id":2352624,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-03-03T21:12:16.000Z","date":"2022-03-01","kind":"tax_withholding","acquired":false,"shares":956,"price":29.87,"value":28555.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 2,763 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":45562,"source":{"system":"sec-edgar","filing":"0000899243-22-009262","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322009262/doc4.xml","form_type":"4"}},{"id":2352623,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-03-03T21:12:16.000Z","date":"2022-03-01","kind":"exercise","acquired":true,"shares":2763,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":46518,"source":{"system":"sec-edgar","filing":"0000899243-22-009262","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322009262/doc4.xml","form_type":"4"}},{"id":2352622,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-03-03T21:12:16.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":472,"price":25.37,"value":11974.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":43755,"source":{"system":"sec-edgar","filing":"0000899243-22-009262","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322009262/doc4.xml","form_type":"4"}},{"id":2412858,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-03T17:44:36.000Z","date":"2022-02-01","kind":"exercise","acquired":false,"shares":3645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":14580,"derivative":{"underlying":"Common Stock","underlying_shares":3645},"source":{"system":"sec-edgar","filing":"0000899243-22-004634","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322004634/doc4.xml","form_type":"4"}},{"id":2412857,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-03T17:44:36.000Z","date":"2022-02-01","kind":"exercise","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":6250,"derivative":{"underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0000899243-22-004634","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322004634/doc4.xml","form_type":"4"}},{"id":2412856,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-02-03T17:44:36.000Z","date":"2022-02-01","kind":"tax_withholding","acquired":false,"shares":2559,"price":29.33,"value":75055.47,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,770 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":43283,"source":{"system":"sec-edgar","filing":"0000899243-22-004634","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322004634/doc4.xml","form_type":"4"}},{"id":2412855,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-02-03T17:44:36.000Z","date":"2022-02-01","kind":"exercise","acquired":true,"shares":6770,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":45842,"source":{"system":"sec-edgar","filing":"0000899243-22-004634","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322004634/doc4.xml","form_type":"4"}},{"id":2547951,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-10-05T16:05:21.000Z","date":"2021-10-01","kind":"exercise","acquired":false,"shares":4375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares vest on a semi-annual basis until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares vest on a semi-annual basis until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":4375,"derivative":{"underlying":"Common Stock","underlying_shares":4375},"source":{"system":"sec-edgar","filing":"0000899243-21-039183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321039183/doc4.xml","form_type":"4"}},{"id":2547950,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-05T16:05:21.000Z","date":"2021-10-01","kind":"tax_withholding","acquired":false,"shares":2170,"price":26.25,"value":56962.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,375 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":39072,"source":{"system":"sec-edgar","filing":"0000899243-21-039183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321039183/doc4.xml","form_type":"4"}},{"id":2547949,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-05T16:05:21.000Z","date":"2021-10-01","kind":"exercise","acquired":true,"shares":4375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":41242,"source":{"system":"sec-edgar","filing":"0000899243-21-039183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321039183/doc4.xml","form_type":"4"}},{"id":2559543,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-09-24T19:00:19.000Z","date":"2021-08-01","kind":"exercise","acquired":false,"shares":3645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":18225,"derivative":{"underlying":"Common Stock","underlying_shares":3645},"source":{"system":"sec-edgar","filing":"0000899243-21-037667","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321037667/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-03"}},{"id":2559542,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-09-24T19:00:19.000Z","date":"2021-08-01","kind":"exercise","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":9375,"derivative":{"underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0000899243-21-037667","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321037667/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-03"}},{"id":2559541,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-24T19:00:19.000Z","date":"2021-08-01","kind":"tax_withholding","acquired":false,"shares":2342,"price":27.33,"value":64006.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,770 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":34697,"source":{"system":"sec-edgar","filing":"0000899243-21-037667","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321037667/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-03"}},{"id":2559540,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-24T19:00:19.000Z","date":"2021-08-01","kind":"exercise","acquired":true,"shares":6770,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":37039,"source":{"system":"sec-edgar","filing":"0000899243-21-037667","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321037667/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-03"}},{"id":2578373,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-09-03T20:01:07.000Z","date":"2021-09-01","kind":"exercise","acquired":false,"shares":2762,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":19340,"derivative":{"underlying":"Common Stock","underlying_shares":2762},"source":{"system":"sec-edgar","filing":"0000899243-21-035223","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321035223/doc4.xml","form_type":"4"}},{"id":2578372,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-03T20:01:07.000Z","date":"2021-09-01","kind":"tax_withholding","acquired":false,"shares":1072,"price":29.85,"value":31999.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 2,762 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":36867,"source":{"system":"sec-edgar","filing":"0000899243-21-035223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321035223/doc4.xml","form_type":"4"}},{"id":2578371,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-03T20:01:07.000Z","date":"2021-09-01","kind":"exercise","acquired":true,"shares":2762,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":37939,"source":{"system":"sec-edgar","filing":"0000899243-21-035223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321035223/doc4.xml","form_type":"4"}},{"id":2578370,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-03T20:01:07.000Z","date":"2021-08-31","kind":"grant","acquired":true,"shares":480,"price":24.39,"value":11707.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":35177,"source":{"system":"sec-edgar","filing":"0000899243-21-035223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321035223/doc4.xml","form_type":"4"}},{"id":2616787,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-08-03T18:09:25.000Z","date":"2021-08-01","kind":"exercise","acquired":false,"shares":3645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":18225,"derivative":{"underlying":"Common Stock","underlying_shares":3645},"source":{"system":"sec-edgar","filing":"0000899243-21-031344","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321031344/doc4.xml","form_type":"4"}},{"id":2616786,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-08-03T18:09:25.000Z","date":"2021-08-01","kind":"exercise","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date.  The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date.  The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":9375,"derivative":{"underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0000899243-21-031344","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321031344/doc4.xml","form_type":"4"}},{"id":2616785,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-08-03T18:09:25.000Z","date":"2021-08-01","kind":"tax_withholding","acquired":false,"shares":2342,"price":27.33,"value":64006.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,770 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":34697,"source":{"system":"sec-edgar","filing":"0000899243-21-031344","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321031344/doc4.xml","form_type":"4"}},{"id":2616784,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-08-03T18:09:25.000Z","date":"2021-08-01","kind":"exercise","acquired":true,"shares":6770,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":37039,"source":{"system":"sec-edgar","filing":"0000899243-21-031344","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321031344/doc4.xml","form_type":"4"}},{"id":2760371,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-04-02T17:08:21.000Z","date":"2021-04-01","kind":"exercise","acquired":false,"shares":4375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares vest on a semi-annual basis (every six months) until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares vest on a semi-annual basis (every six months) until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":8750,"derivative":{"underlying":"Common Stock","underlying_shares":4375},"source":{"system":"sec-edgar","filing":"0000899243-21-014606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321014606/doc4.xml","form_type":"4"}},{"id":2760370,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-04-02T17:08:21.000Z","date":"2021-04-01","kind":"tax_withholding","acquired":false,"shares":1513,"price":42.62,"value":64484.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock sold to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,375 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":30269,"source":{"system":"sec-edgar","filing":"0000899243-21-014606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321014606/doc4.xml","form_type":"4"}},{"id":2760369,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-04-02T17:08:21.000Z","date":"2021-04-01","kind":"exercise","acquired":true,"shares":4375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":31782,"source":{"system":"sec-edgar","filing":"0000899243-21-014606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321014606/doc4.xml","form_type":"4"}},{"id":2811219,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-03-03T19:46:36.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":22102,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date.  The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date.  The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":22102,"derivative":{"underlying":"Common Stock","underlying_shares":22102},"source":{"system":"sec-edgar","filing":"0000899243-21-009554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321009554/doc4.xml","form_type":"4"}},{"id":2811218,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-03T19:46:36.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":38739,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date.  This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":38739,"derivative":{"exercise_price":44.48,"expiration_date":"2031-02-28","underlying":"Common Stock","underlying_shares":38739},"source":{"system":"sec-edgar","filing":"0000899243-21-009554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321009554/doc4.xml","form_type":"4"}},{"id":2811217,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-03T19:46:36.000Z","date":"2021-02-28","kind":"grant","acquired":true,"shares":375,"price":36.21,"value":13578.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":27407,"source":{"system":"sec-edgar","filing":"0000899243-21-009554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321009554/doc4.xml","form_type":"4"}},{"id":2880702,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-02-03T19:16:45.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":3645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":21870,"derivative":{"underlying":"Common Stock","underlying_shares":3645},"source":{"system":"sec-edgar","filing":"0000899243-21-004762","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321004762/doc4.xml","form_type":"4"}},{"id":2880701,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-02-03T19:16:45.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":12500,"derivative":{"underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0000899243-21-004762","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321004762/doc4.xml","form_type":"4"}},{"id":2880700,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-03T19:16:45.000Z","date":"2021-02-01","kind":"tax_withholding","acquired":false,"shares":2458,"price":49.49,"value":121646.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock sold to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,770 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":27032,"source":{"system":"sec-edgar","filing":"0000899243-21-004762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321004762/doc4.xml","form_type":"4"}},{"id":2880699,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-02-03T19:16:45.000Z","date":"2021-02-01","kind":"exercise","acquired":true,"shares":6770,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":29490,"source":{"system":"sec-edgar","filing":"0000899243-21-004762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321004762/doc4.xml","form_type":"4"}},{"id":3012423,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-10-05T19:49:23.000Z","date":"2020-10-01","kind":"exercise","acquired":false,"shares":4375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares vest on a semi-annual basis (every six months) until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares vest on a semi-annual basis (every six months) until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":13125,"derivative":{"underlying":"Common Stock","underlying_shares":4375},"source":{"system":"sec-edgar","filing":"0000899243-20-027383","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320027383/doc4.xml","form_type":"4"}},{"id":3012422,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-10-05T19:49:23.000Z","date":"2020-10-01","kind":"tax_withholding","acquired":false,"shares":2170,"price":57.96,"value":125773.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,375 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":22720,"source":{"system":"sec-edgar","filing":"0000899243-20-027383","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320027383/doc4.xml","form_type":"4"}},{"id":3012421,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-10-05T19:49:23.000Z","date":"2020-10-01","kind":"exercise","acquired":true,"shares":4375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":24890,"source":{"system":"sec-edgar","filing":"0000899243-20-027383","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320027383/doc4.xml","form_type":"4"}},{"id":3068976,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-08-04T21:32:27.000Z","date":"2020-08-01","kind":"exercise","acquired":false,"shares":3645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":25515,"derivative":{"underlying":"Common Stock","underlying_shares":3645},"source":{"system":"sec-edgar","filing":"0000899243-20-021330","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320021330/doc4.xml","form_type":"4"}},{"id":3068975,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-08-04T21:32:27.000Z","date":"2020-08-01","kind":"exercise","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":15625,"derivative":{"underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0000899243-20-021330","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320021330/doc4.xml","form_type":"4"}},{"id":3068974,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-08-04T21:32:27.000Z","date":"2020-08-01","kind":"tax_withholding","acquired":false,"shares":2618,"price":67.48,"value":176662.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,770 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":20515,"source":{"system":"sec-edgar","filing":"0000899243-20-021330","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320021330/doc4.xml","form_type":"4"}},{"id":3068973,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-08-04T21:32:27.000Z","date":"2020-08-01","kind":"exercise","acquired":true,"shares":6770,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":23133,"source":{"system":"sec-edgar","filing":"0000899243-20-021330","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320021330/doc4.xml","form_type":"4"}},{"id":3068972,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-08-04T21:32:27.000Z","date":"2020-07-31","kind":"grant","acquired":true,"shares":316,"price":36.68,"value":11590.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":16363,"source":{"system":"sec-edgar","filing":"0000899243-20-021330","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320021330/doc4.xml","form_type":"4"}},{"id":3123125,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-06-03T19:53:17.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":42400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest in installments conditioned upon the achievement, on or before June 30, 2024, of up to three specified market price thresholds of the Issuer, subject to the Reporting Person's continuous service with the Issuer through each vesting date.  The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest in installments conditioned upon the achievement, on or before June 30, 2024, of up to three specified market price thresholds of the Issuer, subject to the Reporting Person's continuous service with the Issuer through each vesting date.  The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":42400,"derivative":{"underlying":"Common Stock","underlying_shares":42400},"source":{"system":"sec-edgar","filing":"0000899243-20-015159","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320015159/doc4.xml","form_type":"4"}},{"id":3182313,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-04-03T16:07:03.000Z","date":"2020-04-01","kind":"exercise","acquired":false,"shares":4375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares shall vest on a semi-annual basis (every six months) until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The Restricted Stock Units are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares shall vest on a semi-annual basis (every six months) until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The Restricted Stock Units are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":17500,"derivative":{"underlying":"Common Stock","underlying_shares":4375},"source":{"system":"sec-edgar","filing":"0000899243-20-010117","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320010117/doc4.xml","form_type":"4"}},{"id":3182312,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-04-03T16:07:03.000Z","date":"2020-04-01","kind":"tax_withholding","acquired":false,"shares":1513,"price":48.73,"value":73728.49,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,375 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":16047,"source":{"system":"sec-edgar","filing":"0000899243-20-010117","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320010117/doc4.xml","form_type":"4"}},{"id":3182311,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-04-03T16:07:03.000Z","date":"2020-04-01","kind":"exercise","acquired":true,"shares":4375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":17560,"source":{"system":"sec-edgar","filing":"0000899243-20-010117","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320010117/doc4.xml","form_type":"4"}},{"id":3290484,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-04T20:45:30.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":38500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":38500,"derivative":{"exercise_price":65.82,"expiration_date":"2030-02-02","underlying":"Common Stock","underlying_shares":38500},"source":{"system":"sec-edgar","filing":"0000899243-20-003027","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320003027/doc4.xml","form_type":"4"}},{"id":3290483,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-02-04T20:45:30.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":29160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":29160,"derivative":{"underlying":"Common Stock","underlying_shares":29160},"source":{"system":"sec-edgar","filing":"0000899243-20-003027","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320003027/doc4.xml","form_type":"4"}},{"id":3290482,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-02-04T20:45:30.000Z","date":"2020-02-01","kind":"exercise","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date.  The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date.  The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":18750,"derivative":{"underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0000899243-20-003027","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320003027/doc4.xml","form_type":"4"}},{"id":3290481,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-02-04T20:45:30.000Z","date":"2020-02-01","kind":"tax_withholding","acquired":false,"shares":1167,"price":65.26,"value":76158.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 3,125 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":13185,"source":{"system":"sec-edgar","filing":"0000899243-20-003027","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320003027/doc4.xml","form_type":"4"}},{"id":3290480,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-02-04T20:45:30.000Z","date":"2020-02-01","kind":"exercise","acquired":true,"shares":3125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":14352,"source":{"system":"sec-edgar","filing":"0000899243-20-003027","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320003027/doc4.xml","form_type":"4"}},{"id":3290479,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-02-04T20:45:30.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":310,"price":36.68,"value":11370.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":11227,"source":{"system":"sec-edgar","filing":"0000899243-20-003027","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924320003027/doc4.xml","form_type":"4"}},{"id":3400334,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-10-02T19:26:47.000Z","date":"2019-10-01","kind":"exercise","acquired":false,"shares":4375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares vest on a semi-annual basis (every six months) until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares vest on a semi-annual basis (every six months) until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":21875,"derivative":{"underlying":"Common Stock","underlying_shares":4375},"source":{"system":"sec-edgar","filing":"0000899243-19-024773","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924319024773/doc4.xml","form_type":"4"}},{"id":3400333,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-10-02T19:26:47.000Z","date":"2019-10-01","kind":"tax_withholding","acquired":false,"shares":1537,"price":46.99,"value":72223.63,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,375 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":10917,"source":{"system":"sec-edgar","filing":"0000899243-19-024773","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924319024773/doc4.xml","form_type":"4"}},{"id":3400332,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-10-02T19:26:47.000Z","date":"2019-10-01","kind":"exercise","acquired":true,"shares":4375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":12454,"source":{"system":"sec-edgar","filing":"0000899243-19-024773","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924319024773/doc4.xml","form_type":"4"}},{"id":3446649,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-08-05T17:06:52.000Z","date":"2019-08-01","kind":"exercise","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":21875,"derivative":{"underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0000899243-19-021012","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924319021012/doc4.xml","form_type":"4"}},{"id":3446648,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-08-05T17:06:52.000Z","date":"2019-08-01","kind":"tax_withholding","acquired":false,"shares":1081,"price":54.25,"value":58644.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 3,125 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":8079,"source":{"system":"sec-edgar","filing":"0000899243-19-021012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924319021012/doc4.xml","form_type":"4"}},{"id":3446647,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-08-05T17:06:52.000Z","date":"2019-08-01","kind":"exercise","acquired":true,"shares":3125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":9160,"source":{"system":"sec-edgar","filing":"0000899243-19-021012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924319021012/doc4.xml","form_type":"4"}},{"id":3446646,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-08-05T17:06:52.000Z","date":"2019-07-31","kind":"grant","acquired":true,"shares":311,"price":36.68,"value":11407.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":6035,"source":{"system":"sec-edgar","filing":"0000899243-19-021012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924319021012/doc4.xml","form_type":"4"}},{"id":3567459,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-04-02T16:13:17.000Z","date":"2019-04-01","kind":"exercise","acquired":false,"shares":8750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares shall vest on a semi-annual basis (every six months) until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The Restricted Stock Units are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares shall vest on a semi-annual basis (every six months) until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The Restricted Stock Units are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":26250,"derivative":{"underlying":"Common Stock","underlying_shares":8750},"source":{"system":"sec-edgar","filing":"0000899243-19-009557","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924319009557/doc4.xml","form_type":"4"}},{"id":3567458,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-04-02T16:13:17.000Z","date":"2019-04-01","kind":"tax_withholding","acquired":false,"shares":3026,"price":52.9,"value":160075.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 8,750 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":5724,"source":{"system":"sec-edgar","filing":"0000899243-19-009557","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924319009557/doc4.xml","form_type":"4"}}],"next_cursor":"2019-04-02T16:13:17.000000Z,3567458"}